Vertex
Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases. Bringing together the brightest minds, investing in science and taking smart risks, they go all in. For the lives they have changed and for those who are still waiting, Vertex will never stop fighting until they discover cures.
Latest Vertex Content
News
Stem Cell Therapy Helps Control Blood Sugar in Type I Diabetes Trial
An innovative stem cell-based treatment for Type 1 diabetes can meaningfully regulate blood glucose levels and reduce dependence on daily insulin injections, according to new clinical trial results.
Video
Automating Workflows for DMPK Studies - Vertex Pharmaceuticals’ Experience
Are you interested in automating your DMPK assays? Learn how Vertex Pharmaceutical is leveraging the flexibility of Hamilton Liquid handlers to automate multiple workflows on the same deck.
Article
The Next 10 Years: What’s Coming for Gene Editing in the Clinic
The next 10 years will likely bring gene editing to market for an array of rare conditions. However, making the potential benefits broadly available won’t be without roadblocks. Here, we explore some of the issues the industry will have to contend with.
Product News
Vertex and CRISPR Therapeutics Announce MHRA Marketing Authorisation Application Validation for CRISPR/Cas9 Gene-Edited Therapy
The Medicines and Healthcare products Regulatory Agency has validated the Marketing Authorisation Application of exa-cel for the treatment of sickle cell disease and transfusion-dependent beta thalassemia in Great Britain.
Industry Insight
Gene-Edited Stem Cell-Derived Therapies – A Functional Cure for T1D?
Technology Networks spoke with Michael Yang, president and chief executive officer of ViaCyte, to learn more about the development of a stem cell-derived therapy for the treatment of T1D and the technology behind it.
News
Researchers Reveal How Cystic Fibrosis Drugs Bind to Target Protein
A mutated protein causes the genetic disease cystic fibrosis. Now, researchers have solved the structure of the protein and how certain drugs bind to it, unveiling their mode of action.
Advertisement
